Effect of Disease State on Human Carboxylesterase 1 Expression and Activity by Aljutayli, Abdullah
University of Rhode Island 
DigitalCommons@URI 
Open Access Master's Theses 
2016 
Effect of Disease State on Human Carboxylesterase 1 Expression 
and Activity 
Abdullah Aljutayli 
University of Rhode Island, aaljutayli@my.uri.edu 
Follow this and additional works at: https://digitalcommons.uri.edu/theses 
Recommended Citation 
Aljutayli, Abdullah, "Effect of Disease State on Human Carboxylesterase 1 Expression and Activity" (2016). 
Open Access Master's Theses. Paper 892. 
https://digitalcommons.uri.edu/theses/892 
This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion 
in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, 
please contact digitalcommons@etal.uri.edu. 
  
EFFECT OF DISEASE STATE ON HUMAN 
CARBOXYLESTERASE 1 EXPRESSION AND ACTIVITY  
 
BY 
ABDULLAH ALJUTAYLI 
 
 
 
 
A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE 
REQUIREMENTS FOR THE DEGREE OF 
MASTER OF SCIENCE 
IN 
PHARMACEUTICAL SCIENCES 
 
 
 
 
UNIVERSITY OF RHODE ISLAND 
2016 
 MASTER OF SCIENCE IN PHARMACEUTICAL SCIENCES  
 
OF 
 
ABDULLAH ALJUTAYLI 
 
 
 
 
 
 
 
 
 
 
 
APPROVED:  
 
Thesis Committee: 
 
Major Professor Fatemeh Akhlaghi 
 
   Sara Rosenbaum 
 
   Natallia Katenka      
    
      Nasser H. Zawia 
  DEAN OF THE GRADUATE SCHOOL 
 
 
 
 
 
 
 
UNIVERSITY OF RHODE ISLAND 
2016 
 
  
ABSTRACT 
Background:  Human carboxylesterase 1, CES1, is a phase I drug metabolizing 
enzyme that catalyzes the hydrolysis of about 20% of therapeutic agents. Factors, such 
as metabolic syndrome, ethnicity, gender and genetic polymorphism can influence the 
activity and/or the expression of drug metabolizing enzymes. Consequently, these 
factors can affect the pharmacokinetics of drugs leading to toxicity or therapeutic 
failure. 
Objective: The objective of our study is to investigate the possible influence of 
ethnicity, gender, age, genetic polymorphism, metabolic syndrome or fatty liver on 
CES1 gene expression and activity.    
Methods:  Expression of CES1 hepatic mRNA was measured in 89 human livers 
using RT-PCR techniques.  Enzymatic activity of CES1 was measured in S9 fractions 
and cytosols obtained from 40 and 96 human liver donors, respectively. The 
hydrolysis rates of two CES1 specific substrates clopidogrel and oseltamivir to their 
corresponding carboxylic acids were measured using LC-MS/MS methods.  Statistical 
analyses were performed to compare between different groups. 
Results and Conclusions: Our data showed that diabetic subjects had less CES1 
hydrolytic efficiency although our data is limited by the small sample size. In addition, 
African American group had significantly higher CES1 activity as compared to 
Caucasian group.  This result provides potential explanation to the clinical observation 
that African Americans subjects exhibit higher resistance to the CES1 substrates 
clopidogrel. 
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CHAPTER 1 
 
INTRODUCTION 
 
Carboxylesterase1 (CES1) is a member of the mammalian carboxylesterases family of 
α/β-hydrolase fold proteins (Redinbo et al., 2003).  In general, mammalian 
carboxylesterases (CESs) are classified based on their amino acid homology into five 
different groups, CES1-CES5 (Holmes et al., 2010). Among the five, CES1 and CES2 
are considered to be drug metabolizing enzymes and they share 40-50% amino acid 
sequence identity (Imai et al., 2006).  CES1 has a critical function in catalyzing the 
hydrolysis of a large number of endogenous as well as exogenous compounds, 
including drugs and toxins.  Many are commonly prescribed drugs that belong to 
diverse therapeutic classes, including antiplatelet agents, central nervous system 
(CNS) stimulants, antivirals, and anti-hyperlipidemics (Table 1) (Casey Laizure et al., 
2013).  The chemical classes of CES1 substrates are ester, carbamate, thioester and 
amides, but the majority are ester prodrugs.  In contrast to cytochrome P450 (CYP) 
enzymes, our knowledge about CES1 is limited (Casey Laizure et al., 2013).  Inter-
individual variability of CES1 has been reported to be 430-fold for mRNA, 100-fold 
for protein and 127-fold for activity, causing unpredicted toxicity or non-
responsiveness in pharmacological agents that are activated or cleared by this pathway 
(Yang et al., 2009).  Inter-individual variability can be attributed to many factors 
including genetic polymorphism, race, drug-drug interaction, age, and/or different 
diseases (Sanghani et al., 2009) (Xu et al., 2002).  The clinical implications of such 
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variability can be far-reaching.  Therefore, more investigation on the role of CES1 as a 
mediator of drug metabolism and disposition is warranted (Casey Laizure et al., 2013). 
 
Table 1. A number of important CES1 substrates among commonly used pharmacological 
agents (Casey Laizure et al., 2013). 
Therapeutic Class Substrates Product Product activity 
Antiplatelet/Anticoagulant Clopidogrel Clopidogrel 
carboxylate 
Inactive 
2-oxo-clopidogrel 2-oxo-clopidogrel 
carboxylate 
Inactive 
Dabigatran etexilate Dabigatran Active 
Angiotensin-converting enzyme 
inhibitors 
Enalapril Enalaprilat Active 
Imidapril Imidaprilat Active 
Anti-hyperlipidemia agents Simvastatin Dihydroxy acid 
metabolite 
Active 
Fenofibrate Fenofibric acid Active 
CNS agents Methylphenidate Ritalinic acid Inactive 
Immunosuppressive agents Mycophenolate 
mofetil  
Mycophenolic acid Active 
Neuraminidase inhibitor Oseltamivir Oseltamivir 
carboxylic acid 
Active 
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CHAPTER 2 
 
REVIEW OF THE LITERATURE 
 
2.1 First Pass Metabolism 
Hydrolysis and transesterification are the two major reactions catalyzed by CES1 
(Redinbo et al., 2003).  Hydrolysis reactions serve as activation reactions for many 
prodrugs.  Drug development scientists have taken advantage of the CES1 metabolism 
pathway to improve the oral bioavailability of many drugs by making ester prodrugs.  
Ester prodrugs are more lipophilic than both corresponding alcohol and carboxylic 
acid moieties that are part of the ester containing molecule (Merali et al., 2014).  The 
high lipophilicity of prodrugs facilitates passive diffusion through cell membranes, 
resulting in higher oral bioavailability (Merali et al., 2014).  For example, the active 
compound oseltamivir acid is a potent antiviral drug; however, due to its polarity, 
oseltamivir acid is not absorbed well through the gastrointestinal track (GIT).  
However, once synthetized as the corresponding ester (oseltamivir), the oral 
bioavailability reaches more than 80% (Taketani et al., 2007).  CES1 mediated ester 
hydrolysis breaks down the ester bond forming two polar moieties, an alcohol moiety 
and an acyl moiety, facilitating their excretion (Fig. 1) (Merali et al., 2014).  It should 
be noted that not every ester-containing drug is a prodrug.  An ester functional group 
might also be a vital group in the structure of some drugs, such as aspirin and 
clopidogrel (Williams et al., 2008).  For such drugs, CES1 mediated ester hydrolysis 
reaction is a de-activation reaction.  In addition to ester hydrolysis, CES1 catalyzes 
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transesterification conjugation reaction, which occurs in the presence of ethyl alcohol.  
For example, clopidogrel in the presence of ethyl alcohol is transesterified into ethyl 
clopidogrel (Tang et al., 2006).  Another example is the transesterification of cocaine 
into the ethylbenzoylecgonine metabolite that is 10 times more potent (Pennings et al., 
2002). 
 
 
Figure 1. Ester hydrolysis (1), and transesterification (2). 
 
2.2 Tissue Distribution 
All CES enzymes are located in the cytoplasmic and endoplasmic reticulum of the 
cells, and they are widely distributed in many tissues of different mammalians. 
According to Protein Atlas, mRNA levels of CES1 are found in its highest abundance 
in the liver, approximately 50% of its total distribution (www.proteinatlas.org, Last 
accessed June 30, 2016).  The next highest is the gallbladder, making about 20% of 
the total mRNA tissue distribution.  It should be noted that CES1 is not the only 
abundant carboxylesterase in the liver.  Human carboxylesterase 2 (CES2) is abundant 
in the liver as well.  However, CES2 is the predominantly found in the gastrointestinal 
tract, GIT, making about 60% of CES2 mRNA total expression in the whole body 
(Taketani et al., 2007).  In contrast to CYPs, the distribution of CES2 along the entire 
small intestine is relatively constant (Satoh and Hosokawa, 2006).  Figure 2 shows the 
pattern of mRNA tissue expression of both CES1 and CES2 in various tissues. 
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Figure 2. CES1 and CES2 RNA tissue expression. 
 
2.3 Substrate Specificity 
Metabolism mediated by CESs usually lacks binding specificity (Holmes et al., 2010) 
(Hosokawa, 2008).  However, specific preferences have been observed between CES1 
and CES2 enzymes.  It has been reported that CES1 usually prefers substrates with a 
large acyl group and a small alcohol group.  In contrast, CES2 prefers substrates with 
a large bulky alcohol group and a small acyl group.  As shown in Table 2, clopidogrel 
is preferably hydrolyzed by CES1 due to its relatively large acyl group, whereas 
irinotecan is preferably hydrolyzed by CES2 because of its relatively large alcohol 
group.  Furthermore, CESs display stereo-selectivity as well.  For example, DL-threo-
methylphenidate (MPH), a central nervous system stimulant, is mainly metabolized to 
ritalinic acid by CES1.  In addition, hydrolysis efficiency for L-isomer is 6- to7-fold 
higher than the corresponding D-isomer (Sun et al., 2004).  Another example is 
permethrin.  The trans isoform is equally preferred by both CES1 and CES2, but its cis 
isoform is hydrolyzed only by CES2, Figure 3 (Zhu et al., 2000). 
 
 
CES1 RNA Tissue Expression
Liver
Gallbladder
Lung
Adipose tissue
Smooth muscle
Stomach
Prostate
Spleen
Duodenum
Small intestine
Rectum
Colon
Kidney
Others
CES2 RNA Tissue Expression
Liver
Gallbladder
Lung
Adipose tissue
Smooth muscle
Stomach
Prostate
Spleen
Duodenum
Small intestine
Rectum
Colon
Kidney
Others
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Table 2. Differences in substrate preferences for CES1 and CES2. 
 
Figure 3. Stereoselectivity  for CES1 and CES2, adapted from (Zhu et al., 2000) 
 
 
2.4 Species Differences 
Animal models are utilized pre-clinically for prediction of pharmacology, toxicology, 
and pharmacokinetics properties of drugs.  The accuracy of the prediction of drug 
metabolism/elimination is highly dependent on the resemblance between the enzyme 
in the human and the animal model.  Generally, drug biotransformation between 
different species may differ in metabolic pathways and/or reaction velocity (Taketani 
et al., 2007).  Among many species including humans, mice, rats, rabbits, dogs, and 
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monkeys, CESs are the most abundant hydrolases in the small intestine and the liver.  
Although all previously mentioned species share CES1 and CES2 families in their 
livers, protein levels of both enzymes vary widely (Taketani et al., 2007).  In addition, 
protein level of CES1 family was reported to be abundant in the intestines of some 
species, such as monkey and rabbit, in contrast to being absent in human (Taketani et 
al., 2007). 
 
Human plasma contains four esterases, three abundant and one rare, which are 
paraxonase, butrylchoinesterase, albumin, and acetylcholinesterase, respectively.  In 
contrast to other animal species, such as rodents and rabbits, none of the CESs are 
expressed in human plasma (Schopfer et al., 2005).  A single molecule of albumin has 
a weak hydrolytic activity; however, albumin’s significant contribution to hydrolysis 
is due to its high plasma concentration.  The hydrolytic activity of albumin is believed 
to be due to Tyr411 amino acid in human albumin (Hosokawa et al., 1995). 
 
Another important consideration is the level of protein homology between animal and 
human isoenzymes.  Monkey CES1 showed 92.9% homology with human CES1.  On 
the other hand, rabbit CES2 shows only 46.9 homology with human CES2.  In fact, 
due to the differences in selectivity and activity of different species isoforms, 
pharmacological activity and toxicity of CES substrates are difficult to predict based 
on animal models and, as a result, experimental animals typically are not adequate pre-
clinical models for carboxylesterases (Wood et al., 2003). 
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2.5 Effect of Gender 
Gender can influence the activity and expression of drug metabolizing enzymes 
(DMEs).  For example, CYP3A4 activity is reported to be two-times higher in female 
subjects as compared with male subjects (Patrick et al., 2007).  Although the CES1 
gender differences are not well established, some evidence has been reported 
supporting the effect of gender on metabolism of some drugs.  For example, one study 
reported that the CES1 substrates lovastatin and simvastatin, are hydrolyzed more 
efficiently in women than in men (Patrick et al., 2007).  Similarly, another clinical 
study showed differences in response and area under the concentration-time curve 
(AUC) for a dose of 0.3 mg/kg of methylphenidate administered to men and women 
subjects.  The value of AUC (SD), in average, was much higher in men as compared 
with women [93.4 (25.3)  ng  h/ml vs. 73.5 (12.8) ng  h/ml respectively] (Patrick et al., 
2007; Casey Laizure et al., 2013). 
 
2.6 Age-dependent Expression and Activity 
Age can potentially influence many drug metabolizing enzymes including cytochrome 
P450 (CYP) enzymes (Koukouritaki et al., 2004).  The activity of some CYPs (i.e. 
CYP2D6, CYP2C9, and CYP2E1) increase gradually with age (Stevens et al., 2003).  
In contrast, CYP3A7 protein level showed a drastic decrease by more than 60-fold by 
the end of their first birthday (Mehrotra et al., 2016).  The influence of age on CES1 
have been reported by Yang et al. and Zhu et al. (Yang et al., 2009)(Zhu et al, 2009). 
The average expression of CES1 in subjects younger than one year was significantly 
lower in comparison with pooled samples. For example, only 20.3% and 11.1 % of the 
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activity of the pooled samples were observed in 13-day and 30-day old subjects.  
Studies conducted using human liver microsome showed 4-fold and 10-fold higher 
adult CES1 activity compare to children and fetal microsomes, respectively (Yang et 
al., 2009).  Furthermore, the correlation between growth hormone (GH) and CESs 
age-related expression in mice models was studied (Zhu et al., 2009).  However, no 
correlation was observed neither after a short-term treatment with GH (1 day) nor after 
a longer term treatment of 9 days, indicating no contribution of GH to reduced CESs 
expression in young mice. 
The results of Yang et al. were consistent with these findings (Yang et al., 2009).  In 
their study, they grouped livers from 104 subjects into three groups, fetal, child, and 
adults.  The expression and the activity were age related in such that it was higher in 
adults than in children, which was, also, higher than the expression in the fetal group. 
 
2.7 Lipid Metabolism 
The role of CES1 in lipid metabolism is very significant.  For example, CES1 
metabolizes endogenous substrates, such as cholesteryl esterase, triacylglycerol, and 
2-arachidonylglycerol through a mechanism of forming a fatty acyl-enzyme 
intermediate and releasing an alcohol substituent (Merali et al., 2014).  The 
intermediate acyl-enzyme, then, reacts with water releasing an acyl containing-
substrate.  In addition, CES1 possesses cholesterol transferase activity that helps with 
de-esterification and trans-esterification of lipids and forms cholesteryl esters in the 
presence of free cholesterol (Friedrichsen et al., 2013).  Friedrichesn et al. reported a 
correlation between CES1 expression in adipose tissue and obesity, in which CES1 
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expression was higher in obese subjects (Friedrichsen et al., 2013).  Furthermore, diet 
induced weight loss decreased CES1 expression in obese subjects.  In fact, some 
speculate that CES1 expression in adipose tissue is connected to measures of 
metabolic function and obesity, such as plasma insulin level, triglycerides level, waist 
circumference, and homeostasis model assessment-insulin resistance, and, therefore, it 
may contribute to obesity and type-2 diabetes mellitus (Merali et al., 2014). 
 
2.8 Effect of Pathological Conditions 
Disease conditions are another factor that can alter CES1 expression or activity. 
Severe health conditions are accompanied by an elevation in the concentration of 
interleukin 6 (IL-6), an inflammatory biomarker, which has a suppression effect on the 
CES1 expression leading to decreases in CES1 activity (Yang et al., 2007).  Hepatic 
dysfunction, such as cirrhosis and hepatitis, reduces the hydrolysis activity of CES1 
(Thiollet et al., 1992; Eriksson et al., 2003).  However, CES1 expression in mice 
infected with hepatitis C virus was up-regulated, which is believed to help the 
formation of lipid droplets that may be necessary for viral proliferation (Zhu et al., 
2000). 
Type 2 diabetes mellitus was reported to decrease CES1 protein level (Valle et al., 
2012).  Diabetes is characterized by many metabolism disorders including 
hyperglycemia, hyperinsulinemia, and abnormalities in fat, carbohydras and protein 
metabolism (Valle et al., 2012).  Moreover, steatosis and NASH are associated with 
diabetes and obesity (Fabbrini et al., 2010; Leite et al., 2011).  Non-alcoholic fatty 
liver disease (NAFLD) is characterized by steatosis, a condition that is defined as an 
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abnormal retention of lipids in hepatocytes (Merali et al., 2014).  Steatosis per se is an 
independent and important marker for multi-organ insulin resistance (Vega et al., 
2007; Korenblat et al., 2008).  NAFLD can progress to severe stages such as non-
alcoholic steatohepatitis (NASH), cirrhosis or hepatocellular carcinoma (8,9). 
 
2.9 Enzyme Inhibition 
Competitive inhibition is likely to occur between CES1 substrates; especially some of 
CES1 substrates that are commonly prescribed together (Zhu et al., 2000).  For 
example, it is reported that clopidogrel inhibits the conversion of oseltamivir to its 
active metabolite by 90% (Goel et al., 2007).  A clinical trial reported that severe 
mania episode occurred as a result of concurrent administration of aripiprazole and the 
CES1 selective substrate DL-threo-methylphenidate (MPH) (Holmes et al., 2010).  
This effect might be as a result of the aripiprazole potential inhibitory effect on CES1 
metabolism reported in vitro (Zhu et al., 2010). 
 
2.10 Pharmacogenomics and Genetic Polymorphism of CESs 
The highly polymorphic CES1 gene is located on chromosome 16q12.1, and it 
consists of 14 exons (Merali et al., 2014).  Six CES1 single nucleotide polymorphisms 
(SNP) have been identified to be associated with alterations in drug disposition (Hines 
et al., 2016).  The CES1 alleles rs3785161 and rs2241409 are associated with increase 
promoter activity and decreased transcript levels (Marsh et al., 2004; Geshi et al., 
2005). CES1 rs71647871 results in a total loss-of-activity due to a substitution in 
amino acid number 143 from glycine to glutamic acid in the protein product.  This 
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substitution is a result of a nonsynonymous transition of G to A at cDNA position 428 
of CES1 in exon 4 (Hines et al., 2016).  The frequency of this variant is reported to be 
around 4.3% in African Americans, 3.7% in Caucasians, and 2% in Hispanics, and 1% 
in Asians (Casey Laizure et al., 2013). 
 
2.11 Oseltamivir and Clopidogrel 
In our study, we were interested on the role of CES1 in oseltamivir and clopidogrel 
metabolism.  Therefore, both pharmacological agents are reviewed below. 
2.11.1 Oseltamivir 
The World Health Organization (WHO) recommends use of oseltamivir during 
influenza pandemics as a treatment and prevention for influenza A and B virus 
infections (Merali et al., 2014).  Oseltamivir carboxylate, a CES1 metabolism product, 
is the active form of the prodrug oseltamivir.  Oseltamivir carboxylate is a 
neuraminidase inhibitor that prevents viral reproduction.  In vivo and in vitro response 
variability has been reported.  Rs71647871 mutant cell lines showed 25% lower 
activity than the corresponding wild type (Merali et al., 2014).  The average increase 
in the AUC of oseltamivir was 360% and 18% for heterozygotes (428AA) and 
homozygote (428GA) alleles, respectively, compare to the wild type (428GG) allele 
(Taketani et al., 2007).  In healthy volunteers, heterozygous rs121912777 SNP carriers 
showed 18% increase in oseltamivir AUC, and 23% decrease in metabolite-to-drug 
AUC compare to non-carriers (Merali et al., 2014). 
 
2.11.2 Clopidogrel 
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Clopidogrel is a prodrug that undergoes a cascade of biotransformation by several 
CYP enzymes including CYP1A2, CYP3A4, CYP2B6, CYP2C9, and CYP2C19 (Fig. 
4) (Zhu et al., 2013) (Rehmel et al., 2006; Kazui et al., 2010).  However, only 15% of 
the oral dose is metabolized to 2-oxo-clopidogrel and the remaining 85%, undergoes 
hydrolysis by CES1 to the corresponding inactive metabolite (Hagihara et al., 2009).  
The metabolite, 2-oxo-clopidogrel undergoes further metabolism to the 
pharmacologically active 2-thiol clopidogrel (clopidogrel-AM), which is a bio reactive 
compound that irreversibly blocks P2Y12 adenosine diphosphate (ADP) receptor on 
platelet membrane by forming a disulfide bridge (Bouman et al., 2011).  CES1 
dominate the metabolism of both 2-oxo- and 2-thiol-clopidogrel to the inactive 
corresponding carboxylic acids (Bouman et al., 2011). 
 
Prolonged dual antiplatelet therapy with aspirin and clopidogrel, an antiplatelet 
thienopyridine inhibitor, is recommended to reduce ischemic events in 
atherothrombotic patients.  Dual antiplatelet therapy is pivotal in conjunction with the 
use of drug-eluting stents (DES) to prevent stent thrombosis, ST, which is associated 
with high rates of morbidity and mortality (Anderson et al., 2007; Antman et al., 
2008).(Yusuf et al., 2001; Sabatine et al., 2005).  DES is a widely used technique 
making about 75% of the total percutaneous coronary intervention, PCI.  Although the 
dual therapy with clopidogrel and aspirin decreases the occurrence of ST, several 
studies reported rare yet life threating STs in some patients (Vaknin-Assa et al., 2007). 
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A significant inter-individual variability in the response to clopidogrel has been 
reported (Yusuf et al., 2001; Steinhubl et al., 2002; Sabatine et al., 2005).  This 
variability has an impact in a large proportion of the population and increases the risk 
of cardiovascular events in case of hypo-responsiveness (Wang et al., 2006; Angiolillo 
and Alfonso, 2007; Angiolillo et al., 2007; Gurbel et al., 2007).  Many studies have 
associated CYP2C19 reduced-function alleles (*2, *3, *4, *5) with lower levels of 
clopidogrel-AM and consequently lower platelet inhibition and higher rate of adverse 
cardiovascular events, such as ST (Mega et al., 2009; Simon et al., 2009).  However, it 
has been suggested that black race is an independent predictor of definite drug-eluting 
stent thrombosis, and its potential mechanism of influence on ST has been provoked 
for further investigation (Collins et al., 2010).  CES1 is believed to play a major role in 
clopidogrel inter-individual variability and it might explain the mechanism of higher 
cardiovascular events among African American (AA) patients. 
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Figure 4. Metabolic pathways of clopidogrel (Hall et al., 2011). 
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CHAPTER 3 
 
METHODOLOGY 
 
3.1 Chemicals and Supplies 
Oseltamivir, oseltamivir acid, and oseltamivir-d3-acid were obtained from TRC 
(Toronto, ON, Canada).  Clopidogrel and clopidogrel carboxylic acid were purchased 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).  Naproxen was 
purchased from Sigma-Aldrich (St. Louis, MO, USA).  Sections of human livers were 
obtained from a commercial source (Xenotech LLC, Lenexa, KS).  Unless otherwise 
indicated, all other reagents were purchased from Fisher Scientific (Pittsburgh, PA). 
 
3.2 Tissue Preparation 
Human liver samples and their demographic data, i.e. gender, age, height, weight, 
smoking and drinking habits, were obtained from XenoTech LLC. Thawed liver 
samples, 0.5 g each, were homogenized using automated Omni Bead Rutor 24 bead 
mill homogenizer (Omni International, Kennesaw, GA). The homogenates were 
further centrifuged at 10,000 g for 20 min at 4 Co using Eppendorf centrifuge 
(Hamburg, Germany). The supernatant, S9 fractions, were aliquoted and stored for 
further experiments at -80 Co. For microsome and cytosols preparations, the 
supernatants were subjected to ultracentrifugation at 100,000 g for 60 min at 4 Co.  
The pallets were washed and re-suspended in glycerol buffer (20% glycrol, 20 uM 
BHT, 0.5 mM EDTA, 50mM Tris-HCL, and 0.25 M sucrose) and stored in -80 ºC.  
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3.3 Total Protein Quantification 
Total protein concentration in S9, microsomes, and cytosols samples were quantified 
using Bicinchoninic Acid Protein Assay kit (Sigma-Aldrich, St. Louis, MO, USA) 
according to manufacturer’s protocol. 
 
3.4 LC-MS/MS Analyses 
3.4.1 Oseltamivir Assay 
A tandem mass spectrometry technique was used.  Aquiety Xevo TQ MS mass 
spectrometry (Waters Corp.) equipped with an electrospray ionization source (ESI). 
Analytes detection was performed in the positive ion mode, and the mass transitions 
used were m/z 313.11 to 120 with retention time 0.83 minutes for oseltamivir, and m/z 
285.13 to 197 with retention time of 0.75 minutes for oseltamivir acid.  The 
desolvation gas flow rate was 650 L/h at 350 ˚C.  Cone gas flow rate was set at 2 L/h 
and the source temperature was 150˚C. The column was Acquity UPLC BEH C18 
column, 2.1 x 50 mm, 1.7 µm (Waters Corp., Milford, MA) and was maintained at 
45˚C. Mobile phases were (A) 0.05% formic acid and 5% acetonitrile in deionized 
water, and (B) acetonitrile sustained at a flow rate 0.5 ml/min during the entire run of 
2 minutes.  The elution mode was 95:5 (A:B) for 0.1 min.  From 0.1 to 1.0 minutes, 
there was continuous gradient change to A: B 5:95 (v/v).  The composition was kept 
constant for 1.5 minutes.  The mobile phase composition was reversed back with a fast 
gradient to A:B 95:5 (v/v), and the column was re-equilibrated for 2 minutes. 
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The linearity was established from 5 ng/ml to 1000 ng/ml for both oseltamivir and its 
metabolite.  All standards and quality control points were prepared in Tris-HCl buffer 
(50 mM, pH 7.4). Then, they were mixed with 1:2 acetonitrile containing the internal 
standard, oseltamivir-d3-acid, before injecting in the system. 
 
Figure 5. Chromatogram obtained from oseltamivir LC-MS/MS assay. 
 
3.4.2 Clopidogrel Assay 
For clopidogrel LC-MS/MS analysis, the mass transitions used were m/z 322.0 to 
211.85 with retention time 1.6 minutes for clopidogrel, m/z 307.7 to 197 with 
retention time 1.2 minutes clopidogrel carboxylate, and 228.89 to 168.95 for the IS 
naproxen.  . Mobile phases were (A) 0.05% formic acid, and 5% acetonitrile in 
deionized water, and (B) acetonitrile sustained at a flow rate 0.5 ml/min during the 
entire run of 3 minutes.  The elution mode was 95:5 (A:B) for 0.2 min.  From 0.1 to 
1.0 minutes, there was continues gradient change to A: B 5:95 (v/v). The composition 
of mobile phase was kept constant to 2.0 minutes.  It retained back with a fast gradient 
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to A:B 95:5 (v/v), and re-equilibrated until 3 minutes.  The instrument used and its 
parameters were the same as described earlier using the same analytical column. 
The linearity was established from 0.4 ng/ml to 300 ng/ml clopidogrel carboxylic acid.  
All standards and quality control points were prepared as described above with 
oseltamivir. 
Figure 6. Chromatogram obtained from clopidogrel LC-MS/MS assay. 
 
 
3.5 Determination of Enzymatic Activity 
Human carboxylesterase 1, CES1, activity was assessed by the measuring the rate of 
CES1 hydrolysis of the specific substrate, oseltamivir to its carboxylic acid metabolite.  
Oseltamivir hydrolysis was carried out by incubation with human liver cytosols.  With 
30 ul of the reaction buffer, Tris-HCl (50 mM, pH 7.4), containing 0.2 mg/ml protein 
were pipetted into 1 mL Waters 96/well microplates. This was mixed with an equal 
volume of the substrate at concentrations ranged from 9.15 uM to 12.55 mM for S9 
fraction, 10 and 40 uM for cytosols.  After 10 minutes of incubation at 37°C, the 
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reaction was terminated using 120 ul of ice-cold acetonitrile containing the internal 
standard, oseltamivir-d3-acid.  Then, the mixture was centrifuged at 4000 g and 4°C 
for 15 minutes.  Reactions that were performed without protein, served as controls.  
The concentrations of metabolites were measured using the LC-MS/MS method 
described above. 
Clopidogrel incubations with S9 fractions followed the same protocol. However, 
incubation time was 20 min and [S] ranged from 2.24 uM to 605 uM for enzyme 
kinetics and 8 uM for determination of incubation time curves.  
 
For all enzyme kinetics experiments, samples were diluted according to dilution 
factors shown in Table 3 to fit in the range of analysis calibration curve.  
 
Table 3. Dilution factors used in the experiments of determination CES1 enzymatic activity.  
# [Oseltamivir] uM Dilution Factor  [Clopidogrel] uM Dilution Factor 
1 12556 1371.7 605.9 4285 
2 3766.5 411.5 393.8 2785 
3 1130 123.4 256. 1810 
4 339 37 166.4 1176 
5 101.7 11.11 83.2 588 
6 30.51 3.3 24.9 176.5 
7 9.153 1 7.48 53 
8 - - 2.2 15.8 
 
Ahead of all experiments, pilot studies were performed using pooled S9 fractions and 
cytosols from 6 livers of healthy donors to optimize incubation conditions and to 
maintain the reactions in the linear range.  Incubation period (0 to 60 min) and protein 
concentration (0.035 to 1 mg/ml) experiments were performed as described earlier; 
however, using 1.5 ml Eppendorf vials.  
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3.6 Real-Time PCR 
Isolation of total RNA was performed with High Pure RNA Paraffin Kit (Roche 
Diagnostics, Indianapolis, IN, USA).  For cDNA reparation we used QIAamp DNA 
Mini Kit (QIAGEN Sciences, Maryland).  Messenger RNA (mRNA) levels were 
measured using TaqMan Gene Expression Assay (Applied Biosystems, Foster City, 
CA, USA) on a Vii7 real-time PCR machine from Applied Biosystems (Foster City, 
CA).  The results were based on Ct values, which were normalized to B-actin mRNA 
level, and corrected based on 16s rRNA.  
3.7 Statistical Analysis 
The experimental results were analyzed using IBM SPSS Statistics software (Version 
23, Chicago, USA). Results are expressed as the mean ± standard deviation (SD) or 
geometric mean ± SEM. Distribution normality of the variables were confirmed using 
Kolmogorov-Smirnov’s test. Differences between groups were determined using 
either independent samples t-test or nonparametric Kruskal-Wallis test was used as 
specified in each case.  P values of 0.05 or less was considered statistically significant. 
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CHAPTER 4 
 
RESULTS 
 
4.1 Differences in CES1 Expression and Intrinsic Clearances between 
Groups of Subjects Donating Livers  
Differences in CES1 expression and intrinsic clearances between groups of subjects 
donating livers are presented in Table 4 and Table 5, respectively.  Data for the 
factors including fibrosis, NASH or alcohol consumption in Table 5 was not available 
for all subjects. Subjects with diabetes showed significantly higher intrinsic clearance 
(Clint) compare to non-diabetic subjects, P=0.007. Despites the limited sample size of 
6 subjects with probable NASH, it seems that NASH might affect as compare to 
subjects with no NASH, P=0.099.  
 
Table 4.  Differences in CES1 expression levels between groups of subjects donating livers. 
Factor   Variables (N) Mean (SD) ΔΔ CT P Value (Kruskal-
Wallis test) 
Gender Female (43) 
Male (46) 
1.23 (1.04) 
1.82 (2.6) 
0.521 
Race  Caucasian (81) 
African American (8) 
1.60 (2.1) 
0.88 (0.52) 
0.521 
Alcohol Consumption  Yes (45) 
No (44) 
1.66 (1.73) 
1.40 (2.28) 
0.030 
Smoker Yes (47) 
No (42) 
1.55 (1.79) 
1.51 (2.22) 
0.475 
Diabetes No (37) 
Yes (52) 
1.44 (1.82) 
1.59 (2.15) 
0.603 
Fibrosis No (77) 
Yes (12) 
1.58 (2.14) 
1.20 (0.7) 
0.867 
NASH according to 
Kleiner et al. 
classification system 
(Kleiner et al., 2005) 
Not NASH (50) 
Borderline NASH (26) 
NASH (13) 
1.505 (1.76) 
1.58 (2.7) 
1.5 (1.19) 
0.513 
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Table 5.  Differences in intrinsic clearances between groups calculated based on full enzyme kinetics 
obtained from oseltamivir incubations with S9 fraction as determined in Fig. 17.  
 
Factors  Variables (N) Mean (SD) ul/min*mg P Values  
Gender Female (18) 
Male (21) 
160.9 (125.1) 
189.9 (129) 
0.338b  
Race Caucasians (19) 
African Americans  
(20) 
135.33 (98.5) 
215.5 (193.4) 
0.047*a   
 
Alcohol Consumption  Yes (13) 
No (16) 
130.2 (65.7) 
150.2 (104.1) 
0.772a 
Smoker Yes (27) 
No (12) 
180.2 (133) 
168.2 (115.3) 
0.903b 
Diabetes No (27) 
Yes (12) 
204.5  (183.1) 
113.5 (62) 
 
0.007**a  
Fibrosis No (26) 
Yes (3) 
144.9 (91.9) 
109.4 (35.7) 
0.523b 
NASH according to 
Kleiner et al. 
classification system 
(Kleiner et al., 2005) 
Not NASH (22) 
Probable NASH (6) 
158.2 (90.2) 
94.7 (60.2) 
0.099b 
a Independent samples t-test  
b Kruskal-Wallis test 
 
 
4.2 Experiment Conditions  
4.2.1 Time-dependent carboxylesterase 1 activity  
Oseltamivir experiments conditions were determined to be linear in the range of 
experiments as shown in (Fig. 7) for S9 and (Fig. 8) for cytosols pooled from 6 
different subjects.  
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Figure 7. Scatter plot showing incubation time vs. metabolite formation in S9 fraction. 
 
Figure 8. Scatter plot showing incubation time vs. metabolite formation in cytosol. 
 
4.2.2 Establishment of the linearity between protein concentration and hydrolysis 
activity 
Oseltamivir experiments conditions were determined to be linear (Fig. 9) for S9 
and (Fig. 10) for cytosols in the range of the experiments. Cytosol and S9 fractions 
were pooled from 6 different subjects.  
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Figure 9. Scatter plot showing protein concentration vs. oseltamivir carboxylic acid formation 
rate in S9 fractions. 
 
 
 
Figure 10. Scatter plot showing protein concentration vs. oseltamivir carboxylic acid formation 
rate in cytosol. 
 
4.3 Clopidogrel Enzyme Kinetics in S9 fraction 
Pooled liver S9 fractions of 20 AA and 20 Caucasian subjects were used to 
compare CES1 activity in metabolizing clopidogrel to clopidogrel carboxylic acid. 
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The pooled AA group had significantly higher CLint, P =0.036 (Fig. 11).  Substrate 
inhibition was observed and the data were fitted using equation 1. At high substrate 
concentrations, clopidogrel inhibited its own metabolism to clopidogrel carboxylic 
acid in vitro. Clopidogrel was reported to inhibit oseltamivir hydrolysis in vitro (Tang 
et al., 2006). Organic Solvents used to dissolve clopidogrel did not exceed 1%. 
Equation 1: 𝑌 = 𝑉𝑚𝑎𝑥 ∗ !!"!!∗ !!!!"   
 
Figure 11. Clopidogrel incubations in pooled S9 fractions obtained from 20 African American subjects 
and 20 Caucasian subjects showed inhibition effect. 
 
 
4.4 Clopidogrel Hydrolysis Activity as a Function of Time 
Incubations with 8 uM clopidogrel (Fig.12) shows that although both groups were able 
to form 550 nM clopidogrel carboxylic acid, pooled S9 fractions from Caucasians had 
slower reaction time as compared with AA.  This confirms that CES1 activity in AA is 
more efficient even at low substrate concentrations. 
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Figure 12. Pooled Caucasians S9 fractions had slower reaction time as compared with AA. 
 
4.5 Higher CES1 activity in African Americans is Highly Influenced by CES1 
Activity in Five Subjects  
Among the 20 African American subjects, 5 subjects showed relatively and constantly 
higher enzyme activity in metabolizing both clopidogrel and oseltamivir.  When 
removing these subjects, African American group losses the significant level as shown 
in plot with Clint, P<0.0001 (one way ANOVA comparing the three groups) (Fig. 13). 
Figure 13. Among African Americans group, 5 subjects showed three times higher Clint than the 
other groups, P<0.001 (one way ANOVA).  
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4.6 African Americans had Significantly Higher Oseltamivir Hydrolysis 
Rates Compare to Caucasians in Human Liver Cytosol  
The efficiency of hydrolysis 10 uM and 40 uM oseltamivir to oseltamivir carboxylic 
acid expressed as formation rates (pmol/min/mg protein) in human liver cytosols of 8 
African Americans were significantly higher than the rates in cytosols of 88 Caucasian 
subjects indicating higher CES1enzymatic activity in African Americans, P=0.006, 
P=0.002 (Kruskal-Wallis test) for incubations with 10 uM and 40 uM, respectively.  
Data plotted in (Fig. 14) compares the hydrolysis rates of 10 uM oseltamivir in 
African Americans and Caucasians, while (Fig. 15) shows the frequency of 
distribution for incubations with 40 uM.  
 
 
Figure 14. . Boxplot showing oseltamivir carboxylic acid rates of formation of 88 Caucasian and 
8 African American subjects incubation in cytosol at 10 uM. 
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Figure 15. Dot plot showing oseltamivir carboxylic acid rates of formation of 88 Caucasian and 8 
African American subjects (incubation in cytosol at 40 uM). 
4.7 Oseltamivir Enzyme Kinetics Using S9 fractions showed Higher Clint in 
African American Livers 
Averaged and Individual (Fig. 16 A and B) enzyme kinetic results obtained from 
individual incubations in S9 fractions of 20 African Americans showed significantly 
higher internist clearance (Clint) in AA compare to averaged 19 Caucasians, P=0.047. 
Intrinsic clearance was calculated for each subject according to the equation: Clint= 
Vmax/Km. Parameters Km (p=0.05) and Vmax (p= 0.87) were calculated using Prism 
(Table 6). 
 
Figure 16. (A)Averaged and (B) oseltamivir enzyme kinetics. 
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Table 6. Individual Km ,Vmax, and Clint values. 
ID	  	   Km	  
(uM)	  
Vmax	  
(nmol/min/mg)	  
Clint	  
(ul/min*mg)	  
	   ID	  	   Km	  
(uM)	  
Vmax	  
(nmol/min/
mg)	  
Clint	  
(ul/min*mg)	  
AA	   	   Caucasian	  
H0331	   1085.7	   497.3	   458.1	   	   H0415	   1310	   505.49	   385.86	  
H0339	   2303.7	   532.9	   231.3	   	   H0423	   2644	   365.38	   138.19	  
H0379	   995.1	   335.2	   336.9	   	   H0436	   4683.1	   558.86	   119.33	  
H0510	   4449.9	   1044.2	   234.7	   	   H0447	   11229.8	   552.68	   49.22	  
H0533	   2132.6	   296.8	   139.2	   	   H0453	   3189.5	   294.89	   92.45	  
H0561	   3496	   680	   194.5	   	   H0466	   8183	   381.88	   46.67	  
H0566	   1233.6	   680.3	   551.5	   	   H0473	   NA	   NA	   NA	  
H0568	   4155.8	   286.3	   68.9	   	   H0481	   6279.9	   47.23	   7.52	  
H0717	   1258	   333	   264.8	   	   H0484	   11998.1	   1550.81	   129.25	  
H0737	   2376.5	   296.4	   124.7	   	   H0715	   1736.7	   561	   323.07	  
H0749	   1555.2	   270	   173.6	   	   H0741	   5143.9	   461.62	   89.74	  
H0753	   3312.5	   231.1	   69.8	   	   H0745	   2811.4	   530.63	   188.74	  
H0762	   1864.4	   328.2	   176	   	   H0758	   1329.4	   303.6	   228.37	  
H0780	   2957.4	   1049.2	   354.8	   	   H0761	   2609.8	   206.3	   79.05	  
H0803	   1120.7	   133.8	   119.4	   	   H0763	   3653.9	   606.23	   165.92	  
H0805	   1490	   260	   174.6	   	   H0768	   2006.8	   341	   169.96	  
H0828	   6824	   427.7	   62.7	   	   H0791	   1993	   379.26	   190.30	  
H0839	   3755	   506.4	   134.8	   	   H0798	   17702	   289.78	   16.37	  
H0886	   2412	   945.9	   392.2	   	   H0812	   3204.2	   249.12	   77.75	  
H0899	   26540.4	   1282.8	   48.3	   	   H0879	   8707	   641.48	   73.67	  
 
 
 
4.10 Inter Individual Variability in Hydrolysis of Oseltamivir 
Human Carboxylesterase shows high inter-individual variability in both cytosol 
(CV= 66%) and S9 fractions (CV= 73%) as shown in Figures 16 (a) and (b).  
 
 
4.8 Establishment of the correlation between CES1 activities measured by 
oseltamivir and clopidogrel 
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Positive correlation was observed between CES1 activities measured using 
oseltamivir and clopidogrel hydrolysis in S9 fractions (Fig. 17 (a) and (b)).  The data 
used in these correlations are oseltamivir enzyme kinetics data above and clopidogrel 
enzyme kinetics data mentioned in the appendix, which defined the metabolism phase 
by seven [S] points in contrast to 3 [S] points in Figure 11.  
Figure 17 (A). Positive correlation between CES1 activities measured by oseltamivir and 
clopidogrel in African American subjects. 
 
Figure 17 (B).  Positive correlation between CES1 activities measured by oseltamivir and 
clopidogrel in Caucasian subjects. 
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CHAPTER 5 
 
CONCLUSION 
 
The goal of this study was to investigate variables influencing CES1 expression and 
activity, and subsequently the PK/PD of drugs undergo CES1 hydrolysis. Metabolism 
efficiency of oseltamivir mediated by CES1 appeared to be lower in diabetic subjects 
compare to non-diabetic subjects. Despite the limited sample size of 6 subjects with 
probable NASH, it is likely that NASH might reduce the CES1 hydrolysis efficiency. 
However, the effect of both diabetes and NASH should be studied with a larger 
sample size. Also, among many variables, subjects who consume alcohol had higher 
level of CES1 gene expression although it was not translated into higher enzymatic 
activity. 
 
Another important and clinically relevant finding is that African Americans had a 
significantly higher CES1 activity compare to non-African Americans.  This finding 
can provide potential mechanism explaining the clinical observations of African 
Americans developing nearly three times stent thrombosis compare to non-blacks after 
implantation with drug-eluting stent (DES) (Collins et al., 2010).  Our data support 
that black race per se is an independent strong predictor for developing ST after DES 
(Collins et al., 2010).  Our results indicate that CES1 activity in human liver S9 
fractions and Cytosols were significantly higher in Africans American group compare 
to Caucasians using two different CES1 probes, oseltamivir and clopidogrel.  
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In case of clopidogrel metabolism, a two-step metabolism process by CYP1A2 and 
CYP2B6 to clopidogrel thiolacton, and then by CYP2B6, CYP2C9, and CYP2C19 are 
necessary for forming clopidogrel AM.  However, clopidogrel and its metabolites are 
subject to a parallel competitive inactivation pathway.  The inactivation pathway is 
predominant since more than 85% of clopidogrel and 49% of clopidogrel thiolacton is 
inactivated by CES1 to the corresponding carboxylic acid metabolite.  Hydrolysis 
pathway by CES1 is a very efficient pathway compare to CYP450 pathways involved 
in clopidogrel metabolism.  For example, Hagihara et al. reported the mean (activity 
pmol/mg/min) in 20 human liver microsome of CYP1A2 to be (39.0), CYP2B6 (2.0), 
CYP2C9 (54.8), CYP2C19 (10.1), CYP2D6 (27.3), CYP2E1 (1522.4), CYP3A4 
(2084.8), and CES1 to be (20,299.7) (Hagihara et al., 2009).  In addition to CES1 
efficiency over other CYPs, CES1 has a combined effect on clopidogrel metabolism 
such that CES1 is involved in inactivation of clopidogrel and all its metabolites.  
Therefore, due to CES1 efficiency and combined effect, it is very likely that CES1 
activity correlate inversely with clopidogrel AM formed and any variability in CES1 
activity might lead to variation in clopidogrel AM, and consequently its plate 
inhibition activity. However, clopidogrel resistant appears to be multifactorial, and 
some factors, such as CYP2C19 polymorphisms have been reported as contributors.  
  
Clopidogrel inhibited its own metabolism in vitro (Fig. 11).  It was reported that 
clopidogrel inhibited oseltamivir hydrolysis (Shi et al., 2006).  Substrate inhibition 
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was reached at a relatively high concentration and does not seem to have a clinical 
significant.   
 
In contrast to clopidogrel, variability in CES1 activity might not be of a clinical 
implication for drugs that follow sequential non-competitive CES1 metabolism 
pathways, such as oseltamivir.  Assuming enough presentation time to CES1 in the 
liver, CES1 will eventually metabolize all available substrate owning to its high 
efficiency and low in vivo concentration of most drugs.  Such variability in CES1 
activity is likely to be counterbalanced although it might influence some 
pharmacokinetic parameters such as Tmax. 
  
In conclusion, this study gives a potential explanation of the clinical observation and 
strongly supports the conclusion of Collines et al. that black populations are exposed 
to more risk incidence of stent thrombosis (Collins et al., 2010).  Our data support that 
black race per se is a strong predictor of stent thrombosis.
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  APPENDIX  
 
 
I. Results of clopidogrel Incubation, Experiment # 2. 
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